SCHEMBL423849

SCHEMBL423849

Cc1cccc(NC(=O)Nc2cccc(B3OC(C)(C)C(C)(C)O3)c2)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 2/20 0.54
KDR P35968 2/20 0.54
SMN1; SMN2 Q16637 4/20 0.52
KMT2A Q03164 3/20 0.52
PKM P14618 1/20 0.52
SAE1 Q9UBE0 1/20 0.51
UBA2 Q9UBT2 1/20 0.51
ALDH1A1 P00352 1/20 0.51
NPC1 O15118 4/20 0.49
RAB9A P51151 4/20 0.49
HSD17B10 Q99714 1/20 0.49
GBA1 P04062 1/20 0.48
MAPK1 P28482 1/20 0.48
MEN1 O00255 2/20 0.47
MAPT P10636 1/20 0.47
CASP3 P42574 1/20 0.47
SENP7 Q9BQF6 1/20 0.47
SENP6 Q9GZR1 1/20 0.47
EPHX2 P34913 1/20 0.46
GAA P10253 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL423956 0.91 PDGFRB (0.58) PDGFRBKDRSMN1; SMN2KMT2APKM
SCHEMBL15932600 0.91 RAB9A (0.55) PDGFRBKDRSMN1; SMN2KMT2APKM
SCHEMBL5675377 0.89 PDGFRB (0.58) PDGFRBKDRSMN1; SMN2KMT2ANPC1
SCHEMBL556699 0.86 PDGFRB (0.46) PDGFRBKDRSMN1; SMN2KMT2ASAE1
SCHEMBL7139795 0.86 CA1 (0.48) PDGFRBKDRKMT2AHSD17B10MEN1
SCHEMBL60398 0.86 KDR (0.50) PDGFRBKDRSMN1; SMN2KMT2APKM
SCHEMBL561229 0.83 ALDH1A1 (0.50) PDGFRBKDRSMN1; SMN2ALDH1A1RAB9A
SCHEMBL29895479 0.83 ALDH1A1 (0.50) PDGFRBKDRSMN1; SMN2ALDH1A1RAB9A
SCHEMBL21928146 0.83 MEN1 (0.46) PDGFRBKDRSMN1; SMN2KMT2AALDH1A1
SCHEMBL3322268 0.83 LPL (0.45) PDGFRBKDRSMN1; SMN2ALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9163007-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2015-10-20 US disclosed
US-20150232452-A1 NOVEL RAF KINASE INHIBITORS RUGA CORPORATION (US) 2015-08-20 US disclosed
US-8940778-B2 Indazole, benzisoxazole, and benzisothiazole kinase inhibitors ABBVIE INC. (US) 2015-01-27 US disclosed
US-20140343066-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS AbbVie Deutschland GmbH & Co. KG (DE) 2014-11-20 US disclosed
US-20140221374-A1 RAF KINASE INHIBITORS RUGA CORPORATION (US) 2014-08-07 US disclosed
US-8648069-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2014-02-11 US disclosed
US-8642776-B2 Indazole, benzisoxazole, and benzisothiazole kinase inhibitors ABBVIE INC. (US) 2014-02-04 US disclosed
US-20130245015-A1 INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS ABBVIE INC (US) 2013-09-19 US disclosed
EP-2569301-A1 INDAZOLE INHIBITORS OF KINASE Abbvie Inc. (US) 2013-03-20 EP disclosed
US-20130030189-A1 INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS ABBVIE INC. (US) 2013-01-31 US disclosed
EP-2167491-A1 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS Abbott Laboratories (US) 2010-03-31 EP disclosed
US-20090286784-A1 INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-11-19 US disclosed
US-7598283-B2 Indazole, benzisoxazole, and benzisothiazole kinase inhibitors ABBOTT LABORATORIES, INC. (US) 2009-10-06 US disclosed
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-08-13 US disclosed
WO-2008154241-A1 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2008-12-18 WO disclosed
US-20080076767-A1 INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS ABBVIE INC. 2008-03-27 US disclosed
US-7297709-B2 Indazole, benzisoxazole, and benzisothiazole kinase inhibitors ABBOTT LABORATORIES (US) 2007-11-20 US disclosed
EP-1638941-A1 INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS ABBOTT LABORATORIES (US) 2006-03-29 EP disclosed
US-20050020603-A1 Indazole, benzisoxazole, and benzisothiazole kinase inhibitors ABBVIE INC. 2005-01-27 US disclosed
WO-2004113304-A1 INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS ABBOTT LABORATORIES (US) 2004-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130245015-A1 INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS ABL1, BLK, BTK PDGFRB 549/4885KDR 724/4885SMN1; SMN2 4807/4885
US-20140221374-A1 RAF KINASE INHIBITORS BRAF, RAF1, ARAF PDGFRB 973/4885KDR 672/4885SMN1; SMN2 2644/4885
US-20080076767-A1 INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS ABL1, BLK, BTK PDGFRB 549/4885KDR 724/4885SMN1; SMN2 4807/4885
US-20140343066-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 PDGFRB 664/4885KDR 411/4885SMN1; SMN2 3653/4885
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 PDGFRB 664/4885KDR 411/4885SMN1; SMN2 3653/4885
US-20050020603-A1 Indazole, benzisoxazole, and benzisothiazole kinase inhibitors ABL1, BLK, BTK PDGFRB 549/4885KDR 724/4885SMN1; SMN2 4807/4885
US-20090286784-A1 INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS ABL1, BLK, BTK PDGFRB 549/4885KDR 724/4885SMN1; SMN2 4807/4885
US-20150232452-A1 NOVEL RAF KINASE INHIBITORS BRAF, RAF1, ARAF PDGFRB 1143/4885KDR 838/4885SMN1; SMN2 2837/4885
US-20130030189-A1 INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS ABL1, BLK, BTK PDGFRB 549/4885KDR 724/4885SMN1; SMN2 4807/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.